iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and...

iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates - Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201- Clinically meaningful tumor...

iTeos Therapeutics Announces $120 Million Registered Direct Offering - Led by existing investors RA Capital Management and Boxer Capital- Purchase price of $17.50 represents a premium of approximately 44% to last close- Further strengthens balance sheet with pro forma...

Solutran Awarded WIC EBT Contracts for Indian Tribal Organizations MINNEAPOLIS, MN, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Solutran announced that it received awards to provide online and smart card WIC EBT solutions for Indian Tribal Organizations located in Maine and...